라이라 테라퓨틱스(LYRA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.20 (+0.00%), 시가총액 $1.33M, 52주 범위 $0.09 ~ $27.58.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms.
라이라 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
라이라 테라퓨틱스의 현재 주가는 $0.20 (+0.00%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
라이라 테라퓨틱스의 시가총액은 약 $1.33M입니다.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic…